Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elezanumab in Acute Ischemic Stroke (Proof-of-Concept, Double-Blind, Placebo-Controlled)
jRCT2061210064Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in ischemic stroke comparing Elezanumab IV with Placebo IV (2 arms). Primary endpoint: National Institutes of Health Stroke Scale (NIHSS) Total Score During the Treatment Period. Started Jun 2022; status: completed.
02
Drugs
elezanumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on jRCT2061210064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210064.